Core Viewpoint - The company has successfully completed various inspections and obtained necessary permits for its corn protein processing project, which is expected to enhance production capacity and competitive advantage in the domestic feed enzyme protein sector, positively impacting revenue growth and operational quality [1] Group 1 - The company announced that its "annual production capacity of 100,000 tons of corn protein processing project" has completed fire acceptance, safety simultaneous acceptance, and completion acceptance [1] - The company has obtained pollution discharge permits for the project [1] - The wholly-owned subsidiary, Leiling Meinong, received a "Feed Production License" from the Shandong Provincial Animal Husbandry and Veterinary Bureau [1] Group 2 - The project is expected to expand the company's production scale [1] - The project will strengthen the company's competitive advantage in the domestic feed enzyme protein field [1] - The launch of related products is anticipated to have a positive impact on the company's revenue growth and operational quality [1]

Core Viewpoint - Meino Bio (301156.SZ) has made significant progress in its "annual production of 100,000 tons of corn protein deep processing project" by completing various inspections and obtaining necessary permits, which is expected to enhance its competitive advantage in the domestic feed enzymatic protein sector and positively impact revenue growth and operational quality [1][1][1] Group 1 - The company has completed fire acceptance, safety simultaneous acceptance, and completion acceptance for its corn protein project [1] - The company has obtained a pollution discharge permit, marking a critical milestone for the project [1] - The subsidiary, Leiling Meino, has received a feed production license from the Shandong Provincial Animal Husbandry and Veterinary Bureau [1] Group 2 - The project is expected to expand the company's production scale and strengthen its competitive position in the feed enzymatic protein market [1] - The investment aligns with the company's overall strategic planning and supports long-term high-quality development [1] - The investment does not harm the interests of the company or its shareholders, particularly minority shareholders [1]

证券代码：301156 证券简称：美农生物 公告编号：2025-068 上海美农生物科技股份有限公司 关于投资建设年产 10 万吨的玉米蛋白精加工项目进展 暨取得生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 上海美农生物科技股份有限公司（以下简称"公司"）第五届董事会第七次 会议审议通过了《关于对外投资项目的议案》，第五届董事会第九次会议及公司 2024 年第三次临时股东大会审议通过了《关于变更部分募集资金用途、使用部 分募投项目节余资金和超募资金用于投资 10 万吨玉米蛋白精加工项目的议案》， 同意公司设立全资子公司美农生物科技（乐陵）有限公司（以下简称"乐陵美农"） 投资建设"年产 10 万吨的玉米蛋白精加工项目"，并变更部分募集资金用途、 使用部分募投项目节余资金和超募资金用于投资该项目，项目计划投资约 3.91 亿元人民币。董事会授权公司管理层及其授权人士办理相应投资审批备案手续、 签署与本项目相关各类协议、设立子公司等事项。授权期限自公司董事会审议通 过之日起至相关授权事项办理完毕之日止。具体内容详见公司在巨潮资 ...

Core Viewpoint - Shanghai Quanyu Zhihhe Management Consulting Firm (Limited Partnership), a shareholder of Meino Bio (301156.SZ), plans to reduce its holdings by up to 1,407,846 shares, representing no more than 1% of the company's total share capital, within three months after the announcement [1] Group 1 - Quanyu currently holds 8,985,619 shares, accounting for 6.38% of the company's total share capital [1] - The reduction is due to funding needs of some partners within Quanyu [1] - Key individuals, including the actual controller and vice general manager Wang Jihong, as well as director Xiao Weiwei, will not participate in this reduction plan or share in the proceeds from the share reduction [1]

Group 1 - Zijin Mining expects a net profit of approximately 51-52 billion yuan for 2025, representing a year-on-year increase of about 59%-62% due to growth in gold, copper, and silver production and sales prices, along with a significant increase in lithium carbonate production [1] - Tianpu Co. has seen its stock price rise by 718.39% from August 22 to December 30, leading to a suspension for stock trading review due to significant deviation from the company's fundamentals [1] - Salt Lake Co. plans to acquire 51% of Wenkang Salt Lake for 4.605 billion yuan, which will enhance its competitive edge in lithium and potassium resource development [1] Group 2 - Mingde Bio intends to acquire 100% of Wuhan Bikaier Rescue Supplies Co. in a cash transaction, which is expected to constitute a major asset restructuring [2] - Jiamei Packaging has announced that it may apply for a trading suspension if its stock price continues to rise abnormally, despite no significant changes in its fundamentals [2] Group 3 - Jinpan Technology signed a contract worth approximately 696 million yuan for an overseas data center project, which is expected to positively impact the company's long-term performance [3] Group 4 - China Pharmaceutical plans to acquire 70% of Zezheng Pharmaceutical for 525 million yuan [4] - Shengxin Lithium Energy intends to acquire 30% of Qicheng Mining for 2.08 billion yuan to increase its control over Huirong Mining [5] - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for 264 million yuan [5]

Group 1: Share Buybacks - Zhongju Gaoxin plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [3] - Baili Tianheng intends to buy back shares valued at 100 million to 200 million yuan, with a maximum price of 546 yuan per share [3] - Guangqi Technology aims to repurchase shares worth 50 million to 100 million yuan [3] - Proya plans to buy back shares valued at 80 million to 150 million yuan [3] Group 2: Share Reductions - Jiangbolong's senior management has completed the share reduction plan [3] - Hengda New Materials' shareholder Longyou Lianlong plans to reduce its stake by no more than 3% [3] - Guosen Securities' shareholder FAW Investment has reduced its holdings by 22 million shares, completing the reduction plan [3] - United Precision's controlling shareholder He Guijing has cumulatively reduced 319,000 shares from December 29 to 30 [3] - Gu Zhong Technology's senior management Zhou Xiaoqing plans to reduce no more than 0.01% of shares [3] - Huaxing Yuanchuang plans to reduce no more than 434,900 shares already repurchased [3] - Su Shi Testing's controlling shareholder Su Shi General Factory intends to reduce no more than 2% of shares [3] - Chaojie Co. has completed the reduction of 3,985,500 shares [3] - Hongxun Technology's shareholder Bangbangmang plans to reduce no more than 3% of shares [3] - Leiguang Co.'s Xinda Securities has reduced 14.3 million shares, bringing its holding below 5% [3] - Ruihua Tai's shareholder Guotou Gaoke plans to reduce no more than 1% of shares [3] - Meinong Biological's shareholder Quanyu plans to reduce no more than 1% of shares [3] - Youbuxun's controlling shareholder and its concerted parties plan to reduce a total of no more than 2.96% of shares [3] - Wuzhou Xinchun's third-largest shareholder Wuzhou Holdings reduced 10 million shares from November 3 to December 29 [3]

Group 1: Share Buybacks - Zhongju Gaoxin plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [2] - Baili Tianheng intends to repurchase shares for 100 million to 200 million yuan, with a maximum price of 546 yuan per share [2] - Guangqi Technology aims to repurchase shares worth 50 million to 100 million yuan [2] - Proya plans to repurchase shares for 80 million to 150 million yuan [2] Group 2: Share Reductions - Jiangbolong's senior management has completed the share reduction plan [2] - Hengda New Materials' shareholder Longyou Lianlong plans to reduce no more than 3% of the company's shares [2] - Guoxin Securities' shareholder FAW Investment has completed the reduction of 22 million shares [2] - United Precision's controlling shareholder He Guijing reduced 319,000 shares from December 29 to 30 [2] - Su Shiyan's controlling shareholder plans to reduce no more than 2% of shares [2] - Ziguang shares saw a reduction of 14.3 million shares by Cinda Securities, dropping its holding below 5% [2]

Core Viewpoint - The company announced that its shareholder, Shanghai Quanyu Zhihhe Management Consulting Firm (Limited Partnership), plans to reduce its holdings by up to 1,407,846 shares, representing 1% of the total share capital, within three months after the announcement [1] Summary by Relevant Sections - **Shareholder Information** - Shanghai Quanyu holds 8,985,619 shares, accounting for 6.38% of the company's total share capital [1] - **Reduction Plan** - The planned reduction will occur through centralized bidding and will not exceed 1,407,846 shares [1] - **Involvement of Key Personnel** - The actual controller, Wang Jihong, and director, Xiao Weiwei, will not participate in this reduction plan or share in the proceeds from the share reduction [1]

Core Viewpoint - Shanghai Quanyu Zhihhe Management Consulting (Limited Partnership), a shareholder holding 6.38% of Meino Bio (301156), plans to reduce its stake by up to 1% of the total share capital through centralized bidding within three months after 15 trading days [1] Group 1 - The shareholder intends to sell no more than 1,407,800 shares of Meino Bio [1]

Group 1 - The core point of the announcement is that the shareholder, Quan Yu, holds 8.9856 million shares, accounting for 6.38% of the company, and plans to reduce its holdings by up to 1.4078 million shares, which is 1% of the total share capital, within three months after the announcement [1] - The reduction will be executed through centralized bidding, starting 15 trading days after the announcement [1] - Key individuals Wang Jihong and Xiao Weiwei will not participate in this reduction plan or the distribution of its proceeds [1]